Solving the Multimodal Puzzle of Head & Neck Cancer in the Immunotherapy Era

How Evidence is Driving Practice Changes

The Westin Kierland Resort and Spa
Trailblazer A/B
6902 E Greenway Parkway Scottsdale, Arizona 85254
Wednesday, February 14, 2018

6:30 p.m. – 8:00 p.m.

Register Online Here
(Held in conjunction with the Multidisciplinary Head and Neck Cancer Symposium)

Chaired By Ezra Cohen, MD, FRCPC, FASCO
Member – Board Of Trustees, Head and Neck Cancer Alliance

UC San Diego
San Diego Center for Precision Immunotherapy
UC San Diego Moores Cancer Center
La Jolla, California

Activity Description & Educational Objectives

The puzzle of optimal therapy for squamous-cell cancer of the head and neck (SCCHN) is one step closer to being solved with the recent arrival of immunotherapy. Immune stimulation via checkpoint blockade has now joined other effective therapeutic “puzzle pieces” to build an intriguing picture of what multimodal therapy for head and neck cancer (HNC) will look like in the coming years. The key ongoing question, and perhaps the final piece to the puzzle, is how checkpoint inhibition will be integrated into various treatment settings, including as first-line therapy for metastatic disease, as part of treatment for locally advanced HNC, and potentially as a component of adjuvant therapy for resectable disease.

PeerView’s latest interactive, patient voice-inclusive live symposium will attempt to answer this question, and much more, by offering expert views on the most up-to-date evidence supporting the use of checkpoint blockade in various HNC treatment settings and key insights into the future of SCCHN management via the combined use of immunotherapy, radiation, and surgery. That’s not all; this event will also feature voices and views of patients with HNC in collaboration with our educational partner, the Head and Neck Cancer Alliance. Don’t miss this exciting and innovative event!

Upon completion of this activity, participants will be able to:
  • Cite updated evidence on the efficacy of immunotherapy in the SCCHN setting, including data on response, survival, and biomarker-guided treatment
  • Integrate immune checkpoint inhibitors into the management of patients with recurrent/metastatic SCCHN
  • Select patients with SCCHN who are candidates for treatment with immune checkpoint inhibitors in the context of a clinical trial, including individuals with locally advanced or resectable disease
  • Manage immune-related adverse events in patients with SCCHN receiving immunotherapy or multimodal combinations with immunotherapy components

The 2018 Multidisciplinary Head and Neck Cancers Symposium Steering Committee has reviewed and approved this symposium as appropriate for presentation as an Industry Satellite Symposium (ISS). The ISS constitutes the content and views of the sponsor and is not part of the official 2018 Multidisciplinary Head and Neck Cancers Symposium program.

This CME/CE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Merck & Co., Inc.

Register Today

1-866-792-HNCA (4622)

HNCA provides me with the information and support I need. It also provides me with a medium to serve as a role model to others diagnosed with head and neck cancer.”Jason Mendelsohn
Stage-4 HPV-related oral cancer survivor

Thank You to Our Corporate and Community Partners